Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 21, 2003, Pages 3797-3800

  Boschelli, Diane H ^a   Ye, Fei ^a   Wu, Biqi ^a   Wang, Yanong D ^a   Barrios Sosa, Ana Carolina ^a   Yaczko, Deanna ^a   Powell, Dennis ^a   Golas, Jennifer M ^a   Lucas, Judy ^a   Boschelli, Frank ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; ERLOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VANDETANIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; MOUSE; NONHUMAN; RAT; TUMOR XENOGRAFT;

EID: 12444307411     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.07.001     Document Type: Article

References (20)

1. (a) Cohen P. Nat. Rev. Drug Discov. 1:2002;309 (b) Blume-Jensen P., Hunter T. Nature. 411:2001;355.
2. (a) Cohen P. Nat. Rev. Drug Discov. 1:2002;309 (b) Blume-Jensen P., Hunter T. Nature. 411:2001;355.
3. (a) Frame M.C. Biochem. Biophys. Acta. 1602:2002;114 (b) Metcalf C.A. III, van Schravendijk M.R., Dalgarno D.C., Sawyer T.K. Curr. Pharm. Des. 8:2002;2049 (c) Courtneidge S.A. Biochem. Soc. Trans. 30:2002;11.
4. (a) Frame M.C. Biochem. Biophys. Acta. 1602:2002;114 (b) Metcalf C.A. III, van Schravendijk M.R., Dalgarno D.C., Sawyer T.K. Curr. Pharm. Des. 8:2002;2049 (c) Courtneidge S.A. Biochem. Soc. Trans. 30:2002;11.
5. (a) Frame M.C. Biochem. Biophys. Acta. 1602:2002;114 (b) Metcalf C.A. III, van Schravendijk M.R., Dalgarno D.C., Sawyer T.K. Curr. Pharm. Des. 8:2002;2049 (c) Courtneidge S.A. Biochem. Soc. Trans. 30:2002;11.
6. (a) Frame M.C. Biochem. Biophys. Acta. 1602:2002;114 (b) Metcalf C.A. III, van Schravendijk M.R., Dalgarno D.C., Sawyer T.K. Curr. Pharm. Des. 8:2002;2049 (c) Courtneidge S.A. Biochem. Soc. Trans. 30:2002;11.
7. (a) Frame M.C. Biochem. Biophys. Acta. 1602:2002;114 (b) Metcalf C.A. III, van Schravendijk M.R., Dalgarno D.C., Sawyer T.K. Curr. Pharm. Des. 8:2002;2049 (c) Courtneidge S.A. Biochem. Soc. Trans. 30:2002;11.
8. (a) Missbach M., Jeschke M., Feyen J., Muller K., Glatt M., Green J., Susa M. Bone. 24:1999;437 (b) Kraker A.J., Hartl B.G., Amar A.M., Barvian M.R., Showalter H.D.H., Moore C.W. Biochem. Pharm. 60:2000;885 (c) Blake R.A., Broome M.A., Liu X., Wu J., Gishizky M., Sun L., Courtneidge S.A. Mol. Cell Biol. 20:2000;9018.
9. Wang Y.D., Miller K., Boschelli D.H., Ye F., Wu B., Floyd M.B., Powell D.W., Wissner A., Weber J.M., Boschelli F. Bioorg. Med. Chem. Lett. 10:2000;2477.
10. Boschelli D.H., Wang Y.D., Ye F., Wu B., Zhang N., Dutia M., Powell D.W., Wissner A., Arndt K., Weber J.M., Boschelli F. J. Med. Chem. 44:2001;822.
11. Boschelli D.H., Ye F., Wang Y.D., Dutia M., Johnson S., Wu B., Miller K., Powell D.W., Arndt K., Discafani C., Etienne C., Gibbons J., Grod J., Lucas J., Weber J.M., Boschelli F. J. Med. Chem. 44:2001;3965.
12. Golas J.M., Arndt K., Etienne C., Lucas J., Nardin D., Gibbons J., Frost P., Ye F., Boschelli D.H., Boschelli F. Cancer Res. 63:2003;375.
13. All compounds were characterized by MS, NMR and CHN combustion analysis.
14. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., DiOrio C., Doty J., Morin M.J., Moyer M.P., Neveu M., Pollack V.A., Pustilnik L.R., Reynolds M.M., Sloan D., Theleman A., Miller P. Cancer Res. 57:1997;4838 Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., Eckhardt S.G., Tolcher A., Britten C.D., Denis L., Ferrante K., Von Hoff D.D., Silberman S., Rowinsky E.K. J. Clin. Oncol. 19:2001;3267.
15. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., DiOrio C., Doty J., Morin M.J., Moyer M.P., Neveu M., Pollack V.A., Pustilnik L.R., Reynolds M.M., Sloan D., Theleman A., Miller P. Cancer Res. 57:1997;4838 Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., Eckhardt S.G., Tolcher A., Britten C.D., Denis L., Ferrante K., Von Hoff D.D., Silberman S., Rowinsky E.K. J. Clin. Oncol. 19:2001;3267.
16. Hennequin L.F., Stokes E.S.E., Thomas A.P., Johnstone C., Ple P.A., Ogilvie D.J., Dukes M., Wedge S.R., Kendrew J., Curwen J.O. J. Med. Chem. 45:2002;1300 Hennequin, L. F., Thomas, A. P., Johnstone, C., Stokes, E. S. E., Ple, P., Wedge, S. R., Ogilvie, D. J., Kendrew, J., Curwen, J. O., Dukes, M. Proc. Am. Assoc. Cancer Res. 2001, Abstract 3152.
17. Hennequin L.F., Stokes E.S.E., Thomas A.P., Johnstone C., Ple P.A., Ogilvie D.J., Dukes M., Wedge S.R., Kendrew J., Curwen J.O. J. Med. Chem. 45:2002;1300 Hennequin, L. F., Thomas, A. P., Johnstone, C., Stokes, E. S. E., Ple, P., Wedge, S. R., Ogilvie, D. J., Kendrew, J., Curwen, J. O., Dukes, M. Proc. Am. Assoc. Cancer Res. 2001, Abstract 3152.
18. Wissner A., Floyd M.B., Rabindran S.K., Nilakantan R., Greenberger L.M., Shen R., Wang Y.-F., Tsou H.-R. Bioorg. Med. Chem. Lett. 12:2002;2893.
19. 50 values reported represent the means of at least two determinations. The standard deviations (SD) are shown in the brackets.
20. The ethyl ester of 26 has been reported in the literature: Hennequin, L. F.; Pasquet, G. WO 0021955, April 20, 2000; CAN 132:293771.